-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47

Benzinga·11/05/2026 15:20:33
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweight and lowers the price target from $50 to $47.